Targeting a site of vulnerability on circumsporozoite protein inhibits Plasmodium vivax malaria infection.

Targeting the PvCSP-B/NAGG epitope with monoclonal antibody GRAM-4 blocks P. vivax infection stages, offering a new vaccine target with 2.65 Å structural insight.

• Why it matters: Understanding protective B cell epitopes on P. vivax CSP is crucial for developing effective vaccines, as current knowledge gaps hinder progress against malaria caused by this parasite.
• What they did: Researchers identified two key epitopes on PvCSP through plasma screening from infected individuals and isolated the neutralizing monoclonal antibody GRAM-4, which binds the PvCSP-B/NAGG epitope.
• The result: The study demonstrates that targeting this epitope inhibits parasite traversal, hepatocyte invasion, and liver-stage development, paving the way for improved vaccine design based on detailed structural information.